Trospium: Drug information

For additional information see "Trospium: Patient drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: Canada

JAMP-Trospium;
MAR-Trospium;
Trosec

Pharmacologic Category

Anticholinergic Agent

Dosing: Adult

Overactive bladder

Overactive bladder: Oral:

Immediate release: 20 mg twice daily

Extended release: 60 mg once daily in the morning

Dosing: Kidney Impairment: Adult

CrCl ≥30 mL/minute: No dosage adjustment provided in manufacturer's labeling. However, renal impairment increases systemic exposure to trospium. Monitor for increased adverse effects.

CrCl <30 mL/minute:

Immediate release: 20 mg once daily at bedtime

Extended release: Use not recommended

Dosing: Liver Impairment: Adult

Mild impairment: No dosage adjustment provided in manufacturer's labeling.

Moderate to severe impairment: No dosage adjustment provided in manufacturer's labeling; use with caution.

Dosing: Older Adult

Elderly ≥75 years: Immediate release: Consider initial dose of 20 mg once daily (based on tolerability); Extended release: Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Gastrointestinal: Xerostomia (9% to 22%)

1% to 10%:

Cardiovascular: Tachycardia (<2%)

Central nervous system: Headache (4% to 7%), fatigue (2%)

Dermatologic: Skin rash (<2%), xeroderma

Gastrointestinal: Constipation (9% to 10%), abdominal pain (1% to 3%), dyspepsia (1% to 2%), flatulence (1% to 2%), abdominal distention (<2%), nausea (1%), dysgeusia, vomiting

Genitourinary: Urinary tract infection (1% to 7%), urinary retention (≤1%)

Infection: Influenza (2%)

Ophthalmic: Dry eye syndrome (1% to 2%), blurred vision (1%)

Respiratory: Nasopharyngitis (3%), dry nose (1%)

<1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, back pain, chest pain, confusion, delirium, dizziness, drowsiness, fecal impaction, gastritis, hallucination, heat intolerance, hypertensive crisis, inversion T wave on ECG, palpitations, rhabdomyolysis, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, visual disturbance

Contraindications

Hypersensitivity to trospium or any component of the formulation; patients with or at risk of urinary retention, gastric retention, uncontrolled narrow-angle glaucoma

Warnings/Precautions

Concerns related to adverse effects:

• Angioedema: Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported. Immediately discontinue if tongue, hypopharynx, or larynx are involved.

• CNS effects: May cause drowsiness, confusion, dizziness, hallucinations, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

Disease-related concerns:

• Alzheimer's disease: Use with caution in patients with Alzheimer's disease.

• Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.

• Gastrointestinal obstructive disorders: Use with caution in patients with gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention.

• Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.

• Hepatic impairment: Use with caution in patients with moderate or severe hepatic impairment.

• Myasthenia gravis: Use with caution in patients with myasthenia gravis due to decreased GI motility.

• Renal impairment: Use immediate release formulation with caution in patients with renal impairment; dosage adjustment is required. Use of the extended release formulation is contraindicated in patients with severe renal impairment (CrCl <30 mL/minute).

• Ulcerative colitis: Use with caution in patients with ulcerative colitis due to decreased GI motility.

Concurrent drug therapy issues:

• Medications eliminated by active tubular secretion (ATS): ATS is a route of elimination; use caution with other medications that are eliminated by ATS (eg, procainamide, pancuronium, vancomycin, morphine, metformin, and tenofovir).

• Sedatives: Effects with other sedative drugs or ethanol may be potentiated.

Dosage form specific issues:

• Extended release: Ethanol should not be ingested within 2 hours of the administration of the extended release formulation; may increase incidence of drowsiness.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule Extended Release 24 Hour, Oral, as chloride:

Generic: 60 mg

Tablet, Oral, as chloride:

Generic: 20 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsule ER 24 Hour Therapy Pack (Trospium Chloride ER Oral)

60 mg (per each): $6.74 - $10.77

Tablets (Trospium Chloride Oral)

20 mg (per each): $0.50 - $6.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as chloride:

Trosec: 20 mg

Generic: 20 mg

Administration: Adult

Immediate release: Administer with water on an empty stomach at least 1 hour prior to meals.

Extended release: Administer in the morning with water on an empty stomach at least 1 hour before a meal.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsules should be swallowed whole. Do not crush or chew. IR formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.

Use: Labeled Indications

Overactive bladder: Treatment of overactive bladder with symptoms of urgency, incontinence, and urinary frequency

Medication Safety Issues

Older Adult: High-risk medication:

Beers Criteria: Trospium is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of MATE1/2-K, OCT1, OCT2;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Acrivastine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Agents with Clinically Relevant Anticholinergic Effects: May increase anticholinergic effects of Trospium. Risk C: Monitor

Alcohol (Ethyl): May increase CNS depressant effects of Trospium. Management: Avoid consuming any alcohol within 2 hours of taking a dose of trospium XR. Alcohol may increase sedation and CNS depressant effects of trospium XR. Risk D: Consider Therapy Modification

Amantadine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benztropine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Benztropine. Risk C: Monitor

Biperiden: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Biperiden. Risk C: Monitor

Bornaprine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Bromperidol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bromperidol. Risk C: Monitor

Buclizine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Buclizine. Risk C: Monitor

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Chlorprothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Chlorprothixene. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

CloZAPine: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

Cyclizine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Darifenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Darifenacin. Risk C: Monitor

Dicyclomine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dicyclomine. Risk C: Monitor

Dimethindene (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dimethindene (Systemic). Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

Fesoterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Fesoterodine. Risk C: Monitor

FluPHENAZine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrrolate (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Systemic). Risk C: Monitor

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Maprotiline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Maprotiline. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Methotrimeprazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methotrimeprazine. Risk C: Monitor

Methscopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methscopolamine. Risk C: Monitor

Mirabegron: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Mirabegron. Risk C: Monitor

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

OLANZapine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OLANZapine. Risk C: Monitor

Opioid Agonists: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor

Opipramol: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

OxyBUTYnin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OxyBUTYnin. Risk C: Monitor

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Perphenazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Perphenazine. Risk C: Monitor

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Promethazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Promethazine. Risk C: Monitor

Propantheline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Propantheline. Risk C: Monitor

Propiverine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

QuiNIDine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Scopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Scopolamine. Risk C: Monitor

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thiothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Thiothixene. Risk C: Monitor

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tolterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tolterodine. Risk C: Monitor

Topiramate: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Topiramate. Risk C: Monitor

Trimethobenzamide: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trimethobenzamide. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Zuclopenthixol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Zuclopenthixol. Risk C: Monitor

Food Interactions

Ethanol: Ethanol may increase the peak (maximum) serum concentration of trospium when consumed within 2 hours of taking extended release trospium. Management: Avoid consuming any alcohol within 2 hours of taking a dose of extended release trospium.

Food: Administration with a fatty meal reduces the absorption and bioavailability of trospium. Management: Administer 1 hour prior to meals or an empty stomach. Administer extended release capsules in the morning with a full glass of water.

Pregnancy Considerations

Adverse events were observed in animal studies.

Breastfeeding Considerations

It is not known if trospium is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.

Monitoring Parameters

Anticholinergic effects (eg, dry mouth, constipation, dizziness); renal function; postvoid residual urine volume at baseline and as clinically indicated thereafter (AUA [Lerner 2021]); urinary tract infection prior to initiation of therapy (ACOG 2015).

Mechanism of Action

Trospium antagonizes the effects of acetylcholine on muscarinic receptors in cholinergically innervated organs. It reduces the smooth muscle tone of the bladder.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: <10%; decreased with a high-fat meal

Distribution: V_d: 395 to >600 L, primarily in plasma

Protein binding: 48% to 85% in vitro

Metabolism: Hypothesized to be via esterase hydrolysis and conjugation; forms metabolites

Bioavailability: Immediate release formulation: ~10% (range: 4% to 16%)

Half-life elimination: Immediate release formulation: 20 hours

Severe renal insufficiency (CrCl <30 mL/minute): ~33 hours; extended release formulation: ~35 hours

Time to peak, plasma: 5-6 hours

Excretion: Feces (85%); urine (~6%; mostly as unchanged drug) primarily via active tubular secretion

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: In patients with severe renal function impairment, there is a 4.2- and 1.8-fold increase in mean AUC and C_max, respectively, and prolonged elimination t_½.

Hepatic function impairment: In patients with mild or moderate hepatic impairment, the C_max increased 12% and 63%, respectively (immediate release).

Sex: Pharmacokinetic data are conflicting. In patients 60 to 75 years of age, exposure was 45% lower in females compared with males when a single 40 mg immediate-release dose was administered. AUC and C_max were 26% and 68% higher, respectively, in females without hormone therapy compared with males.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Spasmex;
(AR) Argentina: Spasmex;
(AT) Austria: Inkontan | Rekont | Spasmo urgenin trospiumchlorid | Spasmolyt | Trospium aristo | Uraplex | Urivesc;
(BG) Bulgaria: Inkontan;
(BR) Brazil: Spasmex;
(CH) Switzerland: Spasmex | Spasmo-urgenin neo;
(CL) Chile: Spasmex;
(CN) China: Spasmo Lyt;
(CO) Colombia: Floxium;
(CZ) Czech Republic: Spasmex;
(DE) Germany: Ceris | Spasmed | Spasmex | Spasmex TC | Spasmo-urgenin tc | Spasmolyt | Trospi | Trospium Pfleger;
(EC) Ecuador: Trosbio;
(EE) Estonia: Spasmex;
(EG) Egypt: Spasmex | Spasmolyt | Trospamexin | Trospikan;
(ES) Spain: Uraplex;
(FI) Finland: Spasmo Lyt | Spasmo lyt plus | Trospium verman;
(FR) France: Ceris | Trospipharm;
(GB) United Kingdom: Flotros | Regurin | Trospium | Uraplex;
(GR) Greece: Urivesc;
(HK) Hong Kong: Spasmolyt;
(HR) Croatia: Spasmex;
(HU) Hungary: Descalon | Spasmo Lyt;
(IE) Ireland: Flotros | Regurin;
(IL) Israel: Spasmex;
(IN) India: Flotros | Rospium | Tropez od | Trozyd | Trozyd-XR;
(IT) Italy: Spasmolyt | Uraplex | Urivesc;
(JO) Jordan: Spasmex;
(JP) Japan: Cholinerdin | Elist.ace | Kyowamex | Ranoloc | Relaspium | Spasmex;
(KR) Korea, Republic of: Cotro | Inconti | Newropium | Nospa | Prometrium | Sangtros | Spabex | Spasmex | Spasmolyt | Spatro | Spium | Stocpium | Tiromax | Tropa | Tropes | Tropim | Trosmax | Trospol | Troxpid | Wismax;
(KW) Kuwait: Spasmex;
(LB) Lebanon: Spasmex;
(LT) Lithuania: Spasmed | Spasmex;
(LU) Luxembourg: Spasmex | Spasmolyt | Urivesc;
(LV) Latvia: Spasmed | Spasmex;
(MY) Malaysia: Spasmolyt;
(PL) Poland: Spasmex | Spasmo Lyt | Spasmo urgenin tc;
(PR) Puerto Rico: Sanctura | Sanctura xr | Trospium chloride extended release;
(PT) Portugal: Cloreto de trospio Trovain | Cloreto de trospio zentiva | Spasmoplex | Uraplex | Urivesc;
(QA) Qatar: Spasmex;
(RO) Romania: Inkontan;
(RU) Russian Federation: Spasmex | Spasmio lyt;
(SA) Saudi Arabia: Spasmex | Spasmo Lyt | Spasmolyt;
(SG) Singapore: Spasmolyt;
(SI) Slovenia: Spasmex;
(SK) Slovakia: Spasmed | Spasmex;
(TH) Thailand: Spasium | Spasmex | Spasmo Lyt | Urivesc;
(TR) Turkey: Spasmex | Volterra;
(TW) Taiwan: Cololex | Penlex | Spalex | Spasmex | Suraton | Tospin | Uracare;
(VE) Venezuela, Bolivarian Republic of: Uraplex;
(ZA) South Africa: Uricon

2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
Chancellor M and de Miguel F, “Treatment of Overactive Bladder Selective Use of Anticholinergic Agents With Low Drug-Drug Interaction Potential,” Geriatrics, 2007, 62(5):15-24. [PubMed 17489643]
Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. J Urol. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183 [PubMed 34384237]
Staskin D, Sand P, Zinner N, et al, “Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial,” J Urol, 2007, 178(3 Pt 1): 978-84. [PubMed 17632131]
The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. Obstet Gynecol. 2015;126(5):e66-81. [PubMed 26488524]
Trosec (trospium chloride) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; November 2019.
Trospium chloride [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals USA Inc; December 2023.
Trospium chloride ER [prescribing information]. Chantilly, VA: Granules Pharmaceuticals Inc; April 2020.
Zinner N, Gittelman M, Harris R, et al, “Trospium Chloride Improves Overactive Bladder Symptoms: A Multicenter Phase III Trial,” J Urol, 2004, 171(6 Pt 1):2311-15. [PubMed 15126811]

Topic 10320 Version 370.0

خرید پکیج

Trospium: Drug information